Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built for investors. Who's calling the shots? Last week, REX Shares launched the REX Peptide ETF (PEPT), which holds companies (including pharma giants Eli Lilly and Novo Nordisk) that develop and manufacture peptide products, like GLP-1s. AdvisorShares has filed for a competing product, the Peptide and Human Enhancement ETF. There is a growing list of products that try to cash in on the wellness zeitgeist — but much as with GLP-1 users, appetite may be suppressed.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.